Back to Directory Rachael Jeffrey Email rjeffrey@fhi360.org Institution FHI 360 Request an Update Affiliated Studies IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Open to Accrual IMPAACT 2029: Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV DAIDS Number 38717 Research Area Treatment Study Status In Development
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Treatment Study Status Open to Accrual
IMPAACT 2029: Phase I/II Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine among Virologically Suppressed Children and Adolescents Living with HIV DAIDS Number 38717 Research Area Treatment Study Status In Development
